Sep 22, 2026, 8:00 AM EDT · 11 days ago Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
2026-08-06T20:51:28.000Z · 1 month ago Enlivex Therapeutics registers to sell 10M ordinary shares for holders
2026-08-03T10:10:27.000Z · 2 months ago Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright
Jul 30, 2026, 8:00 AM EDT · 2 months ago Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Jul 29, 2026, 8:00 AM EDT · 2 months ago Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Jul 20, 2026, 8:00 AM EDT · 2 months ago Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
2026-07-13T12:26:09.000Z · 2 months ago Enlivex Therapeutics receives RMAT designation for Allocetra from FDA
Jul 13, 2026, 8:00 AM EDT · 2 months ago Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Jul 7, 2026, 8:00 AM EDT · 2 months ago Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Jun 24, 2026, 8:00 AM EDT · 3 months ago Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Jun 22, 2026, 8:45 AM EDT · 3 months ago Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Jun 15, 2026, 8:00 AM EDT · 3 months ago Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Jun 2, 2026, 8:00 AM EDT · 4 months ago ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
Jun 1, 2026, 8:00 AM EDT · 4 months ago Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
May 28, 2026, 8:00 AM EDT · 4 months ago Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
2026-05-27T15:37:44.000Z · 4 months ago Enlivex comments on $100M commitment to Rain’s prediction market
May 27, 2026, 8:00 AM EDT · 4 months ago Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
May 18, 2026, 8:00 AM EDT · 4 months ago Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
May 15, 2026, 4:10 PM EDT · 4 months ago Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Apr 30, 2026, 8:30 AM EDT · 5 months ago Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
Apr 28, 2026, 8:30 AM EDT · 5 months ago Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
Apr 23, 2026, 8:30 AM EDT · 5 months ago Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
2026-04-21T20:54:59.000Z · 5 months ago Enlivex Therapeutics files to sell 23.33M ordinary shares for holders
2026-04-21T12:58:15.000Z · 5 months ago Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra
Apr 21, 2026, 8:30 AM EDT · 5 months ago Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
2026-04-07T10:07:47.000Z · 5 months ago Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright
Mar 26, 2026, 8:30 AM EDT · 6 months ago Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
Mar 25, 2026, 8:30 AM EDT · 6 months ago Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Mar 24, 2026, 8:30 AM EDT · 6 months ago Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
2026-03-23T12:21:45.000Z · 6 months ago Enlivex Therapeutics announces FDA clearance of Allocetra new drug application
Mar 23, 2026, 8:00 AM EDT · 6 months ago Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
2026-02-10T13:11:38.000Z · 7 months ago Enlivex Therapeutics announces new listing of RAIN token on Kraken
Feb 10, 2026, 8:00 AM EST · 7 months ago Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
2026-01-26T13:11:08.000Z · 8 months ago Enlivex Therapeutics announces listing of RAIN token on WhiteBIT
Jan 26, 2026, 8:00 AM EST · 8 months ago Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
2026-01-12T11:10:08.000Z · 8 months ago Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright
Dec 4, 2025, 8:00 AM EST · 10 months ago Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Nov 24, 2025, 10:00 AM EST · 10 months ago Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
Nov 24, 2025, 7:55 AM EST · 10 months ago Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
Nov 24, 2025, 6:40 AM EST · 10 months ago Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
Oct 28, 2025, 8:15 AM EDT · 11 months ago Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Sep 29, 2025, 8:15 AM EDT · 1 year ago D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Sep 11, 2025, 8:00 AM EDT · 1 year ago Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Sep 9, 2025, 8:00 AM EDT · 1 year ago Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Aug 18, 2025, 7:45 AM EDT · 1 year ago Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
Aug 14, 2025, 8:30 AM EDT · 1 year ago Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Jul 28, 2025, 8:30 AM EDT · 1 year ago Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Jun 10, 2025, 8:30 AM EDT · 1 year ago Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Apr 23, 2025, 8:30 AM EDT · 1 year ago Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
Apr 21, 2025, 8:30 AM EDT · 1 year ago Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
Apr 3, 2025, 8:00 AM EDT · 1 year ago Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Mar 17, 2025, 8:00 AM EDT · 1 year ago Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Mar 4, 2025, 4:30 PM EST · 1 year ago Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Mar 3, 2025, 8:22 AM EST · 1 year ago Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
Feb 18, 2025, 6:20 AM EST · 1 year ago Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Jan 10, 2025, 9:00 AM EST · 1 year ago Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV BIAF
Dec 11, 2024, 8:30 AM EST · 1 year ago Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis